By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


SEARCH JOBS

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).


Key Statistics


Email:
Ownership: Public

Web Site: Ariad
Employees:
Symbol: ARIA
 









Company News
Ariad (ARIA) To Webcast Conference Call On Second Quarter 2016 Financial Results 7/5/2016 8:21:11 AM
Ariad (ARIA) Announces Webcast Of Its Annual Stockholders Meeting 6/24/2016 7:44:15 AM
Ariad (ARIA) Completes Strategic Review And Announces Plans For Growth 6/20/2016 11:40:57 AM
Ariad (ARIA) Completes Strategic Review And Announces Plans For Growth 6/17/2016 10:41:37 AM
Ariad (ARIA) Initiates Submission Of New Drug Application For Brigatinib To The U.S. Food And Drug Administration Ahead Of Plan 6/17/2016 8:42:26 AM
Ariad (ARIA) Announces Distribution Agreements For Iclusig In Latin America And The Middle East/North Africa 6/17/2016 8:38:02 AM
Ariad (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase II Pace Clinical Trial 6/13/2016 10:20:22 AM
Ariad (ARIA) To Host Analyst & Investor Day In New York City 6/8/2016 8:46:40 AM
ASCO2016: Ariad (ARIA) Presents Data From Mutational Profiling In Crizotinib-Resistant Patients Treated With Investigational Medicine Brigatinib Showing Similar Response Rates In Patients With And Without Secondary ALK Mutations 6/6/2016 3:14:56 PM
ASCO2016: Ariad (ARIA) Presents Long-Term Phase I/II Trial Follow Up On Investigational Drug Brigatinib With Median Time On Treatment Of 17 Months In ALK+ NSCLC Patients 6/6/2016 2:06:37 PM
12345678910...
//-->